Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk.

Human mutation - 1 Mar 2017

Samuel Nardin, Id Said Badr, Guha Tanya, Novokmet Ana, Li Weili, Silwal-Pandit Laxmi, Børrsen-Dale Anne-Lise, Langerød Anita, Hudson Thomas J, Malkin David

Abstract excerpt

Germline polymorphic variants in cancer predisposition genes such as TP53 have been shown to impact the risk of premenopausal cancer. Accordingly, the aim of this study was to assess the spectrum of polymorphisms in TP53 and its negative regulatory gene, MDM2 (SNP309:T>G) in patients with premenopausal breast cancer. Our findings in a cohort of 40 female patients demonstrate no significant correlation between the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age of Onset
Share to Alleles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to High-Throughput Nucleotide Sequencing

Share to Premenopause

Share to Proto-Oncogene Proteins c-mdm2

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 27957778
DOI: 10.1002/humu.23154

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk.PMID 27957778Read ↗

Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.Semantic proximity Read ↗

The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Significant Association of the MDM2 T309G Polymorphism with Breast Cancer Risk in a Turkish PopulationSemantic proximity Read ↗

No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer.Semantic proximity Read ↗

MDM2 SNP309 is associated with endometrial cancer risk.Semantic proximity Read ↗

No association between the MDM2 -309 T/G promoter polymorphism and breast cancer in African-Americans or Whites.Semantic proximity Read ↗

Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women.Semantic proximity Read ↗

MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis.Semantic proximity Read ↗

The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies.Semantic proximity Read ↗

MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk.Semantic proximity Read ↗

Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.Semantic proximity Read ↗

Association of breast cancer outcome with status of p53 and MDM2 SNP309.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.